BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) was upgraded by analysts at Oppenheimer from a "market perform" rating to an "outperform" rating in a research note issued on Wednesday, Marketbeat.com reports. The firm currently has a $60.00 price target on the stock. Oppenheimer's price objective points to a potential upside of 30.24% from the company's previous close.
A number of other equities research analysts have also recently commented on the stock. Wall Street Zen upgraded shares of BridgeBio Pharma from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Bank of America lifted their price objective on shares of BridgeBio Pharma from $50.00 to $54.00 and gave the company a "buy" rating in a report on Wednesday, June 25th. Redburn Atlantic assumed coverage on shares of BridgeBio Pharma in a research report on Monday, March 31st. They issued a "buy" rating and a $50.00 price objective for the company. JPMorgan Chase & Co. increased their target price on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the company an "overweight" rating in a research report on Monday, March 24th. Finally, UBS Group increased their target price on shares of BridgeBio Pharma from $65.00 to $72.00 and gave the company a "buy" rating in a research report on Wednesday, April 30th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat, BridgeBio Pharma presently has an average rating of "Moderate Buy" and an average price target of $58.93.
Read Our Latest Report on BridgeBio Pharma
BridgeBio Pharma Stock Up 0.2%
Shares of BBIO stock traded up $0.09 during trading hours on Wednesday, hitting $46.07. 1,145,341 shares of the company's stock traded hands, compared to its average volume of 2,521,311. The stock's 50 day simple moving average is $38.37 and its 200 day simple moving average is $35.01. The stock has a market cap of $8.75 billion, a PE ratio of -13.05 and a beta of 1.15. BridgeBio Pharma has a 12 month low of $21.72 and a 12 month high of $46.84.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.12. The business had revenue of $36.74 million for the quarter, compared to the consensus estimate of $57.14 million. During the same period in the previous year, the business posted ($0.20) EPS. BridgeBio Pharma's revenue was down 44.8% on a year-over-year basis. As a group, equities research analysts expect that BridgeBio Pharma will post -3.67 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, Director Frank Mccormick sold 100,000 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $44.23, for a total value of $4,423,000.00. Following the transaction, the director owned 879,979 shares of the company's stock, valued at $38,921,471.17. This represents a 10.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Neil Kumar sold 40,000 shares of the stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $42.54, for a total transaction of $1,701,600.00. Following the completion of the transaction, the chief executive officer directly owned 975,686 shares in the company, valued at $41,505,682.44. The trade was a 3.94% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 9,936,181 shares of company stock worth $375,878,164. Company insiders own 18.20% of the company's stock.
Hedge Funds Weigh In On BridgeBio Pharma
Several institutional investors and hedge funds have recently made changes to their positions in BBIO. First Bank & Trust grew its holdings in BridgeBio Pharma by 3.9% in the 2nd quarter. First Bank & Trust now owns 8,822 shares of the company's stock worth $381,000 after acquiring an additional 329 shares during the last quarter. Ironwood Investment Management LLC lifted its position in BridgeBio Pharma by 0.5% during the 4th quarter. Ironwood Investment Management LLC now owns 63,157 shares of the company's stock valued at $1,733,000 after acquiring an additional 338 shares during the period. GAMMA Investing LLC lifted its position in BridgeBio Pharma by 71.0% during the 1st quarter. GAMMA Investing LLC now owns 920 shares of the company's stock valued at $32,000 after acquiring an additional 382 shares during the period. Xponance Inc. lifted its position in BridgeBio Pharma by 3.8% during the 1st quarter. Xponance Inc. now owns 10,474 shares of the company's stock valued at $362,000 after acquiring an additional 385 shares during the period. Finally, Summit Investment Advisors Inc. increased its stake in BridgeBio Pharma by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 14,706 shares of the company's stock valued at $404,000 after purchasing an additional 466 shares in the last quarter. Institutional investors own 99.85% of the company's stock.
About BridgeBio Pharma
(
Get Free Report)
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Featured Articles

Before you consider BridgeBio Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list.
While BridgeBio Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.